For 503A Sterile Compounders — All 50 US States
Peptide Fulfillment Marketplace
Sterile compounding pharmacies: bid on peptide, GLP-1, HRT, PT-141, and other 503A patient-specific prescriptions. Position early for the RFK-14 reclassification wave.
Why This Window Matters
Feb 27, 2026: HHS Secretary announced ~14 peptides moving from Category 2 back to Category 1. July 23–24, 2026: FDA PCAC recommended six of seven reviewed peptides for the 503A Bulks List. Formal FDA publication pending — but pharmacies positioning now capture the demand.
Priority States
High-density sterile compounding markets with active peptide + longevity clinic demand.
All 50 States
AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyoming